News

Call for tender: Platform for Advanced Virtual Human Twin (VHT) Models

Published on | 1 year ago

Programmes Health AI Continent Deployment: Best use of technologies

The European Commission has published a call for tender (procurement) under the Digital Europe programma for a Platform for Advanced Virtual Human Twin (VHT) Models.

The main objective of this action is to develop a distributed platform making available to users

  1. a federated repository of VHTs related resources,
  2. a combined set of open source software toolkits, and
  3. access to computational services, enabling them to develop, test and integrate VHT models.

The tender and all relevant documents can be found here.

Deadline for receipt of tenders29/05/2024 (16:00)

Deadline until which the tender must remain valid9 Months
Information about public opening: Opening dat 31/05/2024 10:00
 
 

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Latest News

1730 articles available search in articles 

Testimonial

image of Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.